ARCHIVES

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

This article is from The Cancer Letter archive.

Vol. 33 No. 11 | November 26, 2010

Download PDF Visit The Full Archive

Related Articles

FDA Opponents Claim Abuses; Agency Doesn’t Attend Hearing

July 28, 1995

In Brief: Board Subcommittee Meetings On Comprehensive Centers Postponed; FDA Committee Uncharted

March 10, 1978

Facing Congressional Criticism, NIH Starts Review of Extramural Conflict Policies.

June 13, 2008

Uncertainty Lingers After NCI Meeting With Army; Activists Offer Advice

November 6, 1992

Richard Bloch, advocate for patient information services, dead at 78.

July 30, 2004

DCE Board Approves Concepts For Three New RFA Programs

July 6, 1984